Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zhumei Zhan"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The development of lymphoma is a complex multistep process that integrates numerous experimental findings and clinical data that have not yet yielded a definitive explanation. Studies of oncogenic viruses can help to deepen insight into the pathogene
Externí odkaz:
https://doaj.org/article/ae68177876d94b349b3799801667f2e0
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract To investigate the clinical features, survival, and prognostic factors of patients with double primary malignant neoplasms (DPMNs) comprising non-Hodgkin lymphoma (NHL) and malignant solid tumors. Of the 2352 patients diagnosed with NHL, 105
Externí odkaz:
https://doaj.org/article/e735884fc18d4b0195c661702fd07a2d
Autor:
Zhumei Zhan, Wei Guo, Xin Wan, Bowen Wang, Jia Li, Haotian Wang, Zhe Li, Yuhua Huang, Ken H. Young, Ou Bai
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveThe development of diffuse large B-cell lymphoma (DLBCL) is closely related to the host infection status. China is a highly endemic area for hepatitis B virus (HBV) infection. It is not clear whether HBV infection has a consistent effect on
Externí odkaz:
https://doaj.org/article/7164c0eb53a346a0a9902330d2797284
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The ubiquitin-proteasome system (UPS) is involved in various aspects of cell processes, including cell proliferation, differentiation, and cell cycle progression. F-box and WD repeat domain-containing protein 7 (FBW7), as a key component of UPS prote
Externí odkaz:
https://doaj.org/article/89b2ffbda5d348cd853e271266272ba3
Publikováno v:
Blood. 140:11977-11978
Publikováno v:
Annals of hematology.
With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second primary malignancies (SPMs) have become an increasingly relevant long-term concern for NHL survivors. The
Autor:
Fangfang Li, Zhumei Zhan, Ming Hou, Xiangxin Li, Lingling Wang, Wangshan Song, L. Wang, Fanglin Li, Yubin Li, Hao Li
Publikováno v:
Blood. 134:5558-5558
Background: The first-in-class proteasome inhibitor, Bortezomib - based chemotherapy significantly improved the symptoms of multiple myeloma and delayed disease progression. Although the NCCN guidelines recommend twice-weekly 1.3mg/m2, the most appro
Autor:
Fanglin Li, Hao Li, Xiangxin Li, Yan Wang, Yubin Li, Fangfang Li, L. Wang, Lingling Wang, Wangshan Song, Zhumei Zhan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e211